Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests hormone combo to boost IVF success in adenomyosis patients

NCT ID NCT06239376

Disease control Sponsor: Mỹ Đức Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests whether a two-month hormone pretreatment (GnRH agonist plus letrozole) before standard frozen embryo transfer can improve live birth rates in women with adenomyosis. About 222 participants will be randomly assigned to either the new regimen or standard care. The goal is to find a more effective way to prepare the uterus for embryo implantation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GnRH agonist (Diphereline) and letrozole (Femara) followed by estradiol valerate and progesterone
What this could lead to
If successful, this could identify a better way to prepare the uterus for embryo transfer in women with adenomyosis, potentially increasing the chance of a live birth.
What could go wrong
This is a relatively small, early-phase trial (222 participants) comparing two existing protocols, so results may not be definitive or widely applicable. Side effects from the hormone treatments, such as headaches or mood changes, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 222 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 42 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and/or pelvic magnetic resonance imaging. * Age between 18 - 42 * Undergo less or equal to three previous IVF cycles * Indicate for frozen embryo transfer * Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred * Not participating in any other study Exclusion Criteria: * Embryos from IVM cycle * Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity distortion) * Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism * Embryos from the oocyte donation cycle. * Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenomyosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenomyosis ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenomyosis Frozen embryo transfer IVF

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • My Duc Hospital

    RECRUITING

    Ho Chi Minh City, Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.